Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 5;147:1-5.
doi: 10.1017/S0950268818002923. Online ahead of print.

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

F Y Alqahtani  1 , F S Aleanizy  1 , R Ali El Hadi Mohamed  2 , M S Alanazi  3 , N Mohamed  4 , M M Alrasheed  5 , N Abanmy  5 , T Alhawassi  5
Affiliations
Free PMC article

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

F Y Alqahtani et al. Epidemiol Infect. .
Free PMC article
Favorites

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a life-threatening respiratory disease with a high case fatality rate; however, its risk factors remain unclear. We aimed to explore the influence of demographic factors, clinical manifestations and underlying comorbidities on mortality in MERS-CoV patients. Retrospective chart reviews were performed to identify all laboratory-confirmed cases of MERS-COV infection in Saudi Arabia that were reported to the Ministry of Health of Saudi Arabia between 23 April 2014 and 7 June 2016. Statistical analyses were conducted to assess the effect of sex, age, clinical presentation and comorbidities on mortality from MERS-CoV. A total of 281 confirmed MERS-CoV cases were identified: 167 (59.4%) patients were male and 55 (20%) died. Mortality predominantly occurred among Saudi nationals and older patients and was significantly associated with respiratory failure and shortness of breath. Of the 281 confirmed cases, 160 (56.9%) involved comorbidities, wherein diabetes mellitus, hypertension, ischemic heart disease, congestive heart failure, end-stage renal disease and chronic kidney disease were significantly associated with mortality from MERS-CoV and two or three comorbidities significantly affected the fatality rates from MERS-CoV. The findings of this study show that old age and the existence of underlying comorbidities significantly increase mortality from MERS-CoV.

Keywords: Comorbidities; middle east respiratory syndrome coronavirus; mortality.

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. Zaki AM et al. (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine 367, 1814–1820. - PubMed
    1. de Groot RJ et al. (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. Journal of Virology 87, 7790–7792. - PMC - PubMed
    1. (WHO), W.H.O (2017) WHO MERS-CoV Global Summary and Assessment of Risk. Available at http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf.
    1. Chan JF et al. (2015) Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews 28, 465–522. - PMC - PubMed
    1. van Boheemen S et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3, e00473–12. - PMC - PubMed
Feedback